(Q39652063)

English

Correlation between epidermal growth factor receptor-specific nanobody uptake and tumor burden: a tool for noninvasive monitoring of tumor response to therapy

scientific article published on October 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Correlation between epidermal growth factor receptor-specific nanobody uptake and tumor burden: a tool for noninvasive monitoring of tumor response to therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Leo A van Grunsven

6

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Serge Muyldermans

7

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Marleen Keyaerts

object named as

Marleen Keyaerts

2

0 references

author name string

Lea Olive Tchouate Gainkam

1

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Vicky Caveliers

3

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Christian Vanhove

5

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Tony Lahoutte

8

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 October 2011

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Molecular Imaging and Biology

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

940-948

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

https://scigraph.springernature.com/pub.10.1007/s11307-010-0428-4

0 references

Untangling the ErbB signalling network

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

Clinical implications of the mechanism of epidermal growth factor receptor inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT.

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

Potent enzyme inhibitors derived from dromedary heavy-chain antibodies

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

Improved quantification in single-pinhole and multiple-pinhole SPECT using micro-CT information

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

Three-pinhole collimator to improve axial spatial resolution and sensitivity in pinhole SPECT.

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

AMIDE: a free software tool for multimodality medical image analysis

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of D: -luciferin: effect on intensity, time kinetics and repeatability of photon emission.

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review.

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

Whole-body FDG-PET/CT on rheumatoid arthritis of large joints

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography.

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

Nanobodies as tools for in vivo imaging of specific immune cell types

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/micro-CT.

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

Monitoring luciferase-labeled cancer cell growth and metastasis in different in vivo models.

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

Bioluminescent imaging of melanoma in live mice

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK.

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

Erlotinib activates mitochondrial death pathways related to the production of reactive oxygen species in the human non-small cell lung cancer cell line A549.

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0428-4

21 January 2018

Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20865332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EGFR targeting of solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/20865332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20865332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20865332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20865332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo and in vitro uptake of 111In, delivered with the affibody molecule (ZEGFR:955)2, in EGFR expressing tumour cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20865332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20865332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular imaging application of radioiodinated anti-EGFR human Fab to EGFR-overexpressing tumor xenografts

1 reference

https://pubmed.ncbi.nlm.nih.gov/20865332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11307-010-0428-4

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39652063&oldid=1851000501"